Baxter International Inc

These names suffered double-digit losses in October. Should you hold on?

DaVita and Fresenius are best positioned to capture the incremental profits from home therapy.

At Aristotle, the emphasis is on long-term ownership.

Overblown concerns over cable cord-cutters could be opening up opportunities in the media sector. Plus, Ackman's sweet tooth for Mondelez, Priceline still attractive, and more.

We've lowered our fair value estimate, but the shares remain attractive.

The newly independent firm still has a narrow moat, however.

The company faces near-term challenges after the split, but we still like its moat.

Despite the sector looking slightly overvalued, we still see stocks with attractive valuations across the different industries.

Interest-rate fears bring utility and real estate valuations in line, but the broader market still looks fully valued.

Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen.

Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.

While the sector looks slightly overvalued overall, we still see several stocks that offer attractive valuations across the different industries.

Central Bank recipes, leftover housing disappointments, and full valuations may still cause indigestion for investors, says Morningstar markets editor Jeremy Glaser.

These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

While the sector looks fairly valued overall, we still see several stocks that offer attractive valuations across the different industries, including pharmacy benefit managers.

This week: Financial-services firms post lukewarm earnings, two tech giants strike a deal, Time Warner turns down a foxy offer, and more.

In this special midyear presentation, Morningstar's Christine Benz demonstrates how to gauge the viability of your current plan, evaluate positioning, troubleshoot risk factors, and much more.

As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.